1. Introduction {#sec1}
===============

Hearing impairment is a very common sensory disorder, affecting 1 of 500--650 newborns \[[@B1], [@B2]\]. Genetic factors contribute to approximately 60% of congenital sensorineural hearing loss cases. Nonsyndromic hearing loss (NSHL), in which hearing impairment is the only obvious clinical abnormality, accounts for 70% of genetic cases. To date, more than 200 genetic loci have been mapped, and 100 deafness genes have been identified (<http://hereditaryhearingloss.org/>). Autosomal recessive nonsyndromic hearing loss (ARNSHL) is the most common type and accounts for \~80% of cases of inherited hearing loss.

Individuals with mutations in *TMPRSS3* (transmembrane protease, serine 3) present with two different phenotypes: DFNB10-associated hearing impairment that is prelingual (OMIM 605511) and DFNB8-associated hearing impairment that is typically late onset and postlingual (OMIM 601072). *TMPRSS3* mutations can be divided into mild or severe, and the hearing phenotype is dependent upon the combination of two *TMPRSS3* mutations. The combination of two severe mutations leads to prelingual, profound hearing loss, whereas severe mutations in combination with mild mutations lead to a milder phenotype with postlingual-onset hearing loss \[[@B3], [@B4]\]. The genetic load of *TMPRSS3* in ARNSHL varies with ethnicity but is commonly a responsible gene in several populations. The frequency of *TMPRSS3* mutations in childhood ARNSHL cases was 12% (3/25) in Turkish families negative for *GJB2* mutations \[5\]; 13.1% (5/38) in Slovenian ARNSHL patients negative for *GJB2*, *GJB6*, and mitochondrial A1555G mutations \[[@B6]\]; and 0.45% (2/448) in a European population with childhood deafness negative for the *GJB2* 35delG mutation \[[@B7]\]. The frequency is approximately 1.8% (8/449) in the Pakistani population \[[@B8]\], 5% (2/39) in Tunisian families affected by profound ARNSHL \[[@B9]\], 2.5% (1/40) in a Korean ARNSHL study \[[@B10]\], and 5.9% (3/51) in a Korean ARNSHL population negative for the *GJB2* mutation \[[@B11]\]. In some populations, *GJB2* mutations were not excluded and only congenital and profound hearing loss cases were involved. In these populations, *TMPRSS3* mutations might still be a significant cause of deafness.

Although several causative mutations in *TMPRSS3* have been identified, little is known about the contribution of this gene to ARNSHL in the Chinese population. In a prior study, we performed targeted next-generation sequencing of 129 known deafness genes in one Chinese ARNSHL family (FH1523) and identified 3 *TMPRSS3* mutations (c.36delC, c.316C\>T, and c.916G\>A) \[[@B12]\]. In this study, we screened the *TMPRSS3* coding region in 150 ARNSHL families previously shown to lack mutations in *GJB2* or *SLC26A4* genes. In seven families, we identified two known and five novel mutations in *TMPRSS3*. A previously reported mutation (c.916G\>A, p.Ala306Thr) is identified as founder mutation in four families. Our results suggest that mutations in *TMPRSS3* are a relatively common cause for ARNSHL in the Chinese population.

2. Materials and Methods {#sec2}
========================

2.1. Ethics Statement {#sec2.1}
---------------------

This study was approved by the Chinese PLA General Hospital Research Ethics Committee (Beijing, China). Fully informed written consent for participation and for publication of clinical data was obtained from each subject or from the guardians of subjects \< 18 years old (yo).

2.2. Clinical Data {#sec2.2}
------------------

DNA samples from the Departments of Otolaryngology and of Head and Neck Surgery, PLA General Hospital, were analyzed. The 150 affected patients originated from 150 families presenting with ARNSHL, in whom previous screening had found no mutations within the *GJB2* or *SLC26A4* genes. Computed tomography of the temporal bone was performed on the index patients of each family. A physical examination, otoscopy, and pure-tone audiometric examination (at frequencies from 125 to 8000 Hz) were performed to establish the diagnosis of sensorineural hearing loss. The hearing loss range was described based on pure-tone audiometry (PTA) parameters: low frequency, 125--500 Hz; mid frequency, 1-2 kHz; and high frequency, 4--8 kHz. Prelingual and postlingual hearing loss were classified by the onset age of prominent hearing loss. Prelingual hearing loss is present before speech develops and usually begins before age 3, whereas postlingual hearing loss occurs after the development of normal speech \[[@B13]\]. Evaluation of vestibular function included evaluation of the vestibulo-ocular reflex using electronystagmography with computer analysis and saccadic, smooth-pursuit, and horizontal optokinetic nystagmus responses. Vestibular stimulation comprised rotatory and caloric tests.

2.3. DNA Preparation {#sec2.3}
--------------------

All of the genomic DNA was extracted from peripheral blood using a blood DNA extraction kit, according to the manufacturer\'s instructions (TianGen, Beijing, China).

2.4. Mutational Detection and Analysis of *TMPRSS3* {#sec2.4}
---------------------------------------------------

All of the 13 exons and 100 bp of exon-intron boundaries of *TMPRSS3* (NM_024022.2) were screened via Sanger sequencing of DNA from 150 index patients of ARNSHL families. Primer sequences are available upon request. To identify pathogenic mutations, cosegregation analyses were performed with the family members and with an in-house database of 481 Chinese controls with normal hearing.

2.5. Multiple Sequence Alignment {#sec2.5}
--------------------------------

Multiple sequence alignment was performed for the five novel mutations identified, using a HomoloGene package with default settings and the sequences *NP_001243246*.*1* (*H. sapiens*), *XP_001105841*.*2* (*M. mulatta*), *XP_001137100*.*3* (*P. troglodytes*), *XP_001179855*.*1* (*B. taurus*), *XP_853682*.*3* (*C. lupus*), *NP_001157248*.*1* (*M. musculus*), *NP_001101089*.*1* (*R. norvegicus*), *XP_425558*.*3* (*G. gallus*), and *XP_001340422*.*5* (*D. rerio*) (<http://www.ncbi.nlm.nih.gov/homologene?cmd=Retrieve&dopt=MultipleAlignment&list_uids=56985>).

2.6. Haplotype Analysis {#sec2.6}
-----------------------

DNA samples (23) from six families were haplotyped using six STR markers (D21S266, D21S1260, D21S2092, D21S1225, D21S1411, and D21S1890) within a 1 Mb region surrounding *TMPRSS3* Ala306, as previously described ([Table 1](#tab1){ref-type="table"}) \[[@B11]\]. Haplotype analysis was performed by direct sequencing.

3. Results {#sec3}
==========

3.1. Mutation Analysis of *TMPRSS3* {#sec3.1}
-----------------------------------

In our previous study of one Chinese ARNSHL family (FH1523), three disease-segregating mutations in *TMPRSS3* (c.916G\>A, p.Ala306Thr; c.316C\>T, p.Arg106Cys; and c.36delC, p.Pro12fs) were identified and described \[[@B12]\]. In this study, we performed direct sequencing of *TMPRSS3* in probands of another 150 Chinese ARNSHL families negative for *GJB2* and *SLC26A4* mutations. Among these, we identified six families carrying seven causative *TMPRSS3* mutations, including five novel mutations (c.809T\>A, p.Ile270Asn; c.1151T\>G, p.Met384Arg; c.1204G\>A, p.Gly402Arg; c.1244T\>C, p.Leu415Ser; and c.1250G\>A, p.Gly417Glu) and two previously reported pathogenic mutations (c.916G\>A, p.Ala306Thr and c.323-6G\>A) ([Figure 1](#fig1){ref-type="fig"}) \[[@B4], [@B8], [@B14]\]. The five novel mutations were all located within the catalytic serine protease domain. Analysis using Polyphen-2 software predicted them to be damaging, and they were also identified as deleterious by analysis using SIFT. These amino acid substitutions occurred in an evolutionarily conserved region ([Figure 2](#fig2){ref-type="fig"}). They had not been reported in previous studies, were not present in the ExAC database (<http://exac.broadinstitute.org/>), and were not seen in the 481 Chinese controls with normal hearing. Combining the results of this and our previous study, the frequency of *TMPRSS3* mutations found in Chinese ARNSHL families was 4.6% (7/151). The most prevalent mutation was c.916G\>A (p.Ala306Thr) at 2% (6/302), accounting for 47% of all *TMPRSS3* mutations.

3.2. Haplotype Analysis {#sec3.2}
-----------------------

To determine whether the c.916G\>A (p.Ala306Thr) mutation found in families FH1523, 6932, 8082, 8961, 6519, and 10706 was derived from a common founder, we performed linkage analysis using 6 STR markers in 23 DNA samples ([Figure 1](#fig1){ref-type="fig"}, (A)). In four families, we observed linkage disequilibrium between p.Ala306Thr and one STR marker (D21S1260) within a 97 kb interval, while in two of the four families, we found linkage disequilibrium between p.Ala306Thr and two STR markers (D21S1260 and D21S266) within a 359 kb interval, suggesting that p.Ala306Thr probably arose from a common founder, as was previously reported in a Korean population \[[@B11]\].

3.3. Clinical Characteristics and Genotype-Phenotype Correlations {#sec3.3}
-----------------------------------------------------------------

[Table 2](#tab2){ref-type="table"} summarizes clinical characteristics of 14 patients from seven ARNSHL families with *TMPRSS3* mutations including onset age, audiogram configuration, progression of hearing loss, and vestibular symptoms. Age at onset ranged from newborn to 40 years, although the majority of patients showed evidence of deafness in childhood, at 3 to 6 years of age. None of the patients had vestibular symptoms. Examining the types of hearing loss identified some correlations between genotype and phenotype ([Figure 1(B and C)](#fig1){ref-type="fig"}). Hearing loss in 10706-II:1 (male/8 yo) and 10706-II:2 (female/3 yo) ([Figure 1](#fig1){ref-type="fig"}) was diagnosed at 2 yo, and their hearing loss progressed rapidly with age. An audiogram of 10706-II:1 at 8 yo was flat with an average PTA of 90-decibel hearing level (dB HL), whereas that of 10706-II:2 at 3 yo showed ski-slope loss with an average PTA of 85 dB HL. 10706-II:2 underwent cochlear implantation at age 3, and her language ability improved after surgery. The proband and his affected sister were compound heterozygotes for c.916G\>A (p.Ala306Thr) and one novel mutation c.1250G\>A (p.Gly417Glu). In family 6519 ([Figure 1](#fig1){ref-type="fig"}), c.916G\>A (p.Ala306Thr) was detected in patient II:1 in the heterozygous state. The patient\'s mother with normal hearing was also heterozygous for the mutation. No other candidate mutation in the coding region of *TMRPSS3* was detected. Hearing loss in 6519-II:1 ([Figure 1](#fig1){ref-type="fig"}, male/3 yo) was initially detected at age 3, with a ski-slope audiogram and a normal threshold at 250 Hz; the average threshold at 500 Hz to 4 kHz was 55 dB HL. We speculated that a gene copy number variation might exist, that a mutation may lie within a noncoding region, or that other deafness genes were responsible. Hearing loss in 6932-II:1 ([Figure 1](#fig1){ref-type="fig"}, female/17 yo) was initially detected by the age of 9 yo with a ski-slope audiogram. The threshold at 125 and 250 Hz was 10 dB HL and that at 2 Hz to 8 kHz was greater than 100 dB HL. The patient complained of slowly progressing hearing loss with age. She underwent cochlear implantation at age 14, and her language ability improved after surgery. Patient 6932-II:1 was a compound heterozygote for c.916G\>A (p.Ala306Thr) and c.323-6G\>A; both mutations were previously reported. The splice site mutation c.323-6G\>A was reported to be pathogenic in Dutch and Pakistani patients \[[@B3], [@B8]\]. However, there was inconsistency in this classification for the c.323-6G\>A (p.Cys107fs) mutation. In the Dutch family, the c.323-6G\>A mutation was (relatively) severe and homozygous mutation results in prelingual (DFNB10) hearing impairment. However, a homozygous c.323-6G\>A mutation was described by Veske et al. (1996) to be the underlying cause of postlingual (DFNB8) hearing impairment. In this study, considering the hearing phenotype of 6932-II:1, we classified c.323-6G\>A as a mild mutation.

Hearing loss in 8082-II:1 ([Figure 1](#fig1){ref-type="fig"}, female/5 yo) was initially detected at 5 yo with a ski-slope audiogram. Her parents had noticed occasional poor hearing since she was 3 yo. At age 5, she showed severe hearing loss at 1--8 kHz and moderate hearing loss at 250--500 Hz, with a normal threshold at 125 Hz. Thereafter, the hearing loss showed slow progression, with annual threshold deteriorations of 5--8 dB HL at 500 Hz and 2.5--5 dB HL at 1--8 kHz, according to a recent audiogram at 7 yo. She is now wearing hearing aids. Patient 8082-II:1 was a compound heterozygote for c.916G\>A (p.Ala306Thr) and the novel mutation c.809T\>A (p.Ile270Asn). The novel missense mutation c.809T\>A is located within exon 9 and causes an amino acid substitution from isoleucine to asparagine at position 270, which is close to the active site histidine (H257), and therefore affects the activity of the enzyme. Hearing loss of 8961-II:1 ([Figure 1](#fig1){ref-type="fig"}, male/6 yo) was initially detected by the age of 2, with the auditory brainstem response (ABR) threshold for both ears significantly elevated to 97 dB HL. According to the parent\'s description, hearing loss progressed slowly. A recent audiogram at 6 yo was flat, and the average PTA was more than 90 dB HL. Patient 8961-II:1 was a compound heterozygote for c.916G\>A (p.Ala306Thr) and the novel mutation c.1204G\>A (p.Gly402Arg). Hearing loss in M234-II:1 (female/35 yo) and M234-II:3 (male/27 yo) ([Figure 1](#fig1){ref-type="fig"}) was detected at 3 yo, and their hearing loss progressed rapidly with advancing age. An audiogram of M234-II:3 at 27 yo was flat, and the average PTA was more than 90 dB HL, while that of M234-II:1 at 35 yo was a ski-slope, with an average PTA of 75 dB HL. The two patients carried two of the novel mutations as compound heterozygotes: c.1151T\>G (p.Met384Arg) and c.1244T\>C (p.Leu415Ser). Family FH1523 has previously been described \[[@B12]\]. According to the onset and severity of hearing loss, the five novel missense mutations were classified as severe mutations, while c.323-6G\>A was probably a mild mutation.

4. Discussion {#sec4}
=============

The function of TMPRSS3 is very important to the auditory system; it has also been identified as a tumor-associated gene that is overexpressed in pancreatic, ovarian, and breast tumors \[[@B15]--[@B17]\]. In 2001, Scott et al. showed that *TMPRSS3* was mutated in nonsyndromic autosomal recessive deafness (DFNB8/10) and is associated with both congenital and childhood-onset forms \[[@B14]\]. TMPRSS3 contains a transmembrane domain, a low-density lipoprotein receptor class A domain, a scavenger receptor cysteine-rich domain, and a trypsin-like serine protease domain (NP_001243246.1). TMPRSS3 is expressed in spiral ganglion neurons, inner hair cells, supporting cells, and stria vascularis of the rat cochlea \[[@B18]\]. It plays an important role in activating the ENaC sodium channel, which is regulated by serine protease activity \[[@B19]\], and maintains a low Na^+^ concentration in the endolymph of the inner ear \[[@B3], [@B18], [@B20]\].

The typical ski-slope audiogram configuration in ARNSHL is suggestive of *TMPRSS3* involvement, with a hearing phenotype and inheritance similar to those of *SLC26A4*. Our results indicate that *TMPRSS3* mutations account for about 4.6% (7/151) of ARNSHL in Chinese patients negative for *GJB2* and *SLC26A4* mutations, an incidence similar to that seen in Korean and Tunisian populations \[[@B9], [@B11]\]. It has been reported that mutations in different domains of TMPRSS3 result in various hearing impairment phenotypes, likely due to the distinct influence on protease activity of different mutations \[[@B3], [@B5], [@B7]--[@B11], [@B14], [@B18], [@B21]--[@B29]\]. Lee et al. proposed that disruption of the proteolytic activity of TMPRSS3 is tightly correlated with the pathogenesis of hearing loss and predicted that mutations in the SRCR and LDLRA domains affect the proper folding or assembly of the catalytic domain or alter protease substrate recognition and binding \[[@B3]\].

*TMPRSS3* mutations can be classified as mild or severe, and the hearing phenotype is dependent on the combination of the two *TMPRSS3* mutant alleles. Compound heterozygosity for a mild and severe mutation leads to postlingual hearing loss (DFNB8), whereas the combination of two severe mutations leads to profound hearing impairment with prelingual onset (DFNB10) \[[@B4]\]. Apparently, genotype-phenotype correlations can be drawn based on the position or the truncating/nontruncating nature of the *TMPRSS3* mutations.

Our study expanded the mutation spectrum of *TMPRSS3*. [Table 3](#tab3){ref-type="table"} summarizes the type, position, origin, and mutation classification of the 39 *TMPRSS3* mutations reported to date, which are associated with ARNSHL in more than 15 ethnic groups worldwide. Eleven mutations were truncating and were predicted to lead to a prematurely terminated protein product or to nonsense-mediated decay of the mRNA, while another 28 *TMPRSS3* mutations were missense mutations leading to single amino acid substitutions. Almost all of the mutations were predicted to disrupt the proteolytic activity of the protein. The hearing impairment in these families was prelingual or postlingual, mostly with a typical ski-slope audiogram configuration. Consistent with previous reports, the *TMPRSS3* mutations identified in this study were associated with progressive hearing loss with considerable variability in the age of onset and degree of severity and this variability in hearing phenotype was both interfamilial and intrafamilial. The mutation summary data ([Table 3](#tab3){ref-type="table"}) shows that not only protein-truncating mutations (frameshift, stop codon, and splice site mutations) but also missense mutations, particularly those located within the catalytic serine protease domain or close to the active site, have severe effects.

We observed that four combinations of *TMPRSS3* mutations resulted in prelingual, profound hearing impairment: c.1250G\>A (p.Gly417Glu) and c.916G\>A (p.Ala306Thr), c.1204G\>A (p.Gly402Arg) and c.916G\>A (p.Ala306Thr), c.809T\>A (p.Ile270Asn) and c.916G\>A (p.Ala306Thr), and c.1151T\>G (p.Met384Arg) and c.1244T\>C (p.Leu415Ser). The combination of c.323-6G\>A and c.916G\>A (p.Ala306Thr) was manifested by postlingual, milder hearing impairment. Our data suggest that the five novel missense mutations identified in this study have relatively severe effects. *TMPRSS3* c.916G\>A (p.Ala306Thr), which was identified in five families from this study and one family from a previous study, is a pathogenic mutation in German, Dutch, and Korean deaf patients \[[@B4], [@B10], [@B11], [@B21]\], indicating that this mutation is the main contributor to the DFNB8/DFNB10 phenotype in many ethnicities. The proposal by Chung et al. that p.Ala306Thr could be a "founder mutation" was supported by the observation of linked haplotypes of STR markers segregating with hearing loss in two families \[[@B11]\]. Our haplotype analysis of six families showed linkage disequilibrium in four of them. Therefore, we propose that *TMPRSS3* c.916G\>A (p.Ala306Thr) is likely to be a founder mutation in the Chinese population. Combining the data from this study and our previous work, we determined that mutations in *TMPRSS3* are a pathogenic cause of deafness in 7 of 151 (4.6%) Chinese families with ARNSHL. To the best of our knowledge, this is the first study to investigate the etiological contribution of *TMPRSS3* to deafness in a Chinese population.

This study had two minor limitations. First, there are no precise criteria for classifying mutations as severe or mild; therefore, we drew our own conclusions based only on the age of onset and severity of hearing loss. Second, we did not test for copy number variants in the samples; this remains an area for a future study.

In summary, combined with our previous study, we have described the clinical and genetic characteristics of seven Chinese families with ARNSHL carrying causative *TMPRSS3* mutations, resulting in the *TMPRSS3* mutation spectrum to be reported in a Chinese ARNSHL population for the first time. This should have an important impact on clinical patient management, genetic counseling, molecular diagnosis, and the development of advanced therapeutic strategies.
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![Pedigree, haplotype analysis, audiogram, and mutational analysis of families with *TMPRSS3* mutations. (A) Affected subjects are denoted in black. The proband is indicated by an arrow. Haplotype analysis in six families with the recurrent mutation TMPRSS3 p.Ala306Thr. Haplotypes are shown with the linked haplotype in boxes. A recombination event between p.Ala306Thr and D21S1225 was observed in four families while recombination event between p.Ala306Thr and D21S1411 was observed in two families. (B) DNA sequencing profile. (C) Audiograms of the affected subjects. Hearing loss appears to be progressive (red, right ear; blue, left ear).](NP2017-3192090.001){#fig1}

![Conservation analysis of *TMPRSS3* mutations and genomic structure of *TMPRSS3* based on the open reading frame (NM_024022.2). Protein alignment showing conservation of residues TMPRSS3 Ile270, Met384, Gly402, Leu415, and Gly417 across nine species. All mutations occurred at evolutionarily conserved amino acids or areas (in red box) in trypsin-like serine protease domain. TM: transmembrane domain; LDLRA: LDL receptor-like domain; SRCR: scavenger receptor cysteine-rich domain; serine protease: trypsin-like serine protease domain.](NP2017-3192090.002){#fig2}

###### 

Distance of STR marker to TMPRSS3 Ala306.

  STR marker   Distance to A306
  ------------ ------------------
  D21S266      1,117,653
  D21S1260     1,006,184
  D21S266      312,954
  Ala306       0
  D21S1260     97,528
  D21S266      358,798

###### 

Clinical features and *TMPRSS3* mutation combinations of affected family members identified in the present study and our previous study.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Family number             Mutation 1                 Mutation 2                 Patient number                                                                                         Phenotype                                                                                                    Age of onset   Progression   Vertigo
  ------------------------- -------------------------- -------------------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------ -------------- ------------- ---------
  FH1523                    c.36delC (p.Pro12fs)       c.916G\>A (p.Ala306Thr)    1                                                                                                      Downsloping audiogram configuration with impairment of the low frequencies except 125 Hz at 3 years of age   Newborn        Yes           No

  c.316C\>T (p.Arg106Cys)   c.916G\>A (p.Ala306Thr)    5                          Downsloping audiogram configuration with normal threshold of the low frequencies at 50 years of age\   20--30 yo                                                                                                    Yes            No            
                                                                                  Flat audiogram configuration with thresholds of about 80 dB at over 60 years of age                                                                                                                                                              

  6519                      ---                        c.916G\>A (p.Ala306Thr)    1                                                                                                      Moderate slope audiogram configuration with normal threshold of 250 Hz at 3 years of age                     3 yo           Yes           No

  6932                      c.323-6G\>A                c.916G\>A (p.Ala306Thr)    1                                                                                                      Downsloping audiogram configuration with normal hearing threshold of 125 Hz and 256 Hz at 14 years of age    9 yo           Yes           No

  8082                      c.809T\>A (p.Ile270Asn)    c.916G\>A (p.Ala306Thr)    1                                                                                                      Downsloping audiogram configuration with impairment of the low frequencies at a very young age               3 yo           Yes           No

  10706                     c.1250G\>A (p.Gly417Glu)   c.916G\>A (p.Ala306Thr)    2                                                                                                      Flat audiogram configuration with thresholds of about 90 dB at 8 years of age                                2 yo           Yes           No

  8961                      c.1204G\>A (p.Gly402Arg)   c.916G\>A (p.Ala306Thr)    1                                                                                                      Flat audiogram configuration with average PTA is are over 90 dB at 6 yo                                      2 yo           Yes           No

  M234                      c.1151T\>G (p.Met384Arg)   c.1244T\>C (p.Leu415Ser)   2                                                                                                      Flat audiogram configuration with average PTA is over 90 dB at 27 yo\                                        3 yo           Yes           No
                                                                                                                                                                                         Downsloping audiogram configuration with impairment of the low frequencies at 35 yo                                                       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Overview of *TMPRSS3* mutations described in DFNA8/10, including those identified in the present study.

  ------------------------------------------------------------------------------------------------------------------------------------------
  Mutation               Protein change   Exon      Domain            Origin           Mutation classification   Reference
  ---------------------- ---------------- --------- ----------------- ---------------- ------------------------- ---------------------------
  c.323-6G\>A                             Intron4   LDLRA             Chinese\         Mild                      Present study\
                                                                      Korean                                     Ahmed et al., 2004\
                                                                                                                 Weegerink et al., 2011

  c.809T\>A              p.Ile270Asn      E9        Serine protease   Chinese          Severe                    Present study

  c.916G\>A              p.Ala306Thr      E9        Serine protease   Chinese\         Severe                    Present study\
                                                                      German\                                    Gao et al., 2017\
                                                                      Korean\                                    Chung et al., 2014\
                                                                      Dutch                                      Lee et al., 2013\
                                                                                                                 Weegerink et al., 2011

  c.1151T\>G             p.Met384Arg      E11       Serine protease   Chinese          Severe                    Present study

  c.1204G\>A             p.Gly402Arg      E12       Serine protease   Chinese          Severe                    Present study

  c.1244T\>C             p.Leu415Ser      E12       Serine protease   Chinese          Severe                    Present study

  c.1250G\>A             p.Gly417Glu      E12       Serine protease   Chinese          Severe                    Present study

  c.36delC               p.Pro12fs        E2        TM                Chinese          Severe                    Gao et al., 2017

  c.36dupC               p.Phe13fs        E2        TM                Turkish          N/A                       Diaz-Horta et al., 2011

  c.208delC              p.Thr70fs        E4        LDLRA             Pakistani\       Severe                    Ahmed et al., 2004\
                                                                      Spanish\                                   Weegerink et al., 2011\
                                                                      Greek\                                     Battelino et al., 2016
                                                                      Newfoundlander                             

  c.268G\>A              p.Ala90Thr       E4        LDLRA             UK Caucasian\    N/A                       Charif et al., 2012
                                                                      Moroccan                                   

  c.296C\>A              p.Ser99X         E4        LDLRA             Chinese          Severe                    Gu et al., 2014

  c.308A\>G              p.Asp103Gly      E4        LDLRA             Greek            N/A                       Wattenhofer et al., 2002

  c.310G\>A              p.Glu104Lys      E4        LDLRA             Pakistani        N/A                       Lee et al., 2012

  c.310G\>T              p.Glu104X        E4        LDLRA             Pakistani        N/A                       Lee et al., 2012

  c.316C\>T              p.Arg106Cys      E4        LDLRA             Chinese\         Mild                      Gao et al., 2017\
                                                                      Japanese                                   Miyagawa et al., 2013

  c.325C\>T              p.Arg109Trp      E5        SRCR              Pakistani\       Severe                    Ahmed et al., 2004\
                                                                      Korean                                     Ben-Yosef et al., 2001

  c.326G\>A              p.Arg109Gln      E5        SRCR              Chinese          Mild                      Gu et al., 2014

  c.413C\>G              p.Ala138Glu      E5        SRCR              British\         Mild                      Weegerink et al., 2011
                                                                      Korean                                     

  c.581G\>T              p.Cys194Phe      E6        SRCR              Pakistani        Severe                    Ahmed et al., 2004\
                                                                                                                 Ben-Yosef et al., 2001

  c.595G\>A              p.Val199Met      E6        SRCR              Dutch\           Severe                    Weegerink et al., 2011
                                                                      Korean                                     

  c.607C\>T              p.Gln203X        E6        SRCR              Japanese         Severe                    Miyagawa et al., 2013

  c.646C\>T              p.Arg216Cys      E8        SRCR              German           Mild                      Elbracht et al., 2007

  c.647G\>T              p.Arg216Leu      E8        SRCR              Turkish          Severe                    Wattenhofer et al., 2005

  c.726C\>G              p.Cys242Trp      E8        SRCR              Pakistani        Severe                    Shafique et al., 2014

  c.743C\>T              p.Thr248Met      E8        SRCR              Korean           Mild                      Chung et al., 2014

  c.753G\>C              p.Trp251Cys      E8        SRCR              Tunisian         Severe                    Masmoudi et al., 2001

  c.767C\>T              p.Arg256Val      E8        SRCR              Pakistani        N/A                       Lee et al., 2012

  c.782+8insT                             Intron8   SRCR              Newfoundlander   Severe                    Ahmed et al., 2004

  c.988delA              p.Glu330fs       E10       Serine protease   Pakistani        Severe                    Walsh et al., 2005

  c.1019C\>G             p.Thr340Arg      E10       Serine protease   Italian          Severe                    Vozzi et al., 2014

  c.1159G\>A             p.Ala387Thr      E11       Serine protease   Japanese         Mild                      Miyagawa et al., 2013

  c.1180_1187del8ins68                    E11       Serine protease   Palestinian      Severe                    Scott et al., 2001

  c.1192C\>T             p.Gln398X        E12       Serine protease   Turkish          Severe                    Wattenhofer et al., 2005

  c.1211C\>T             p.Pro404Leu      E12       Serine protease   Tunisian         Severe                    Wattenhofer et al., 2005\
                                                                                                                 Masmoudi et al., 2001

  c.1219T\>C             p.Cys407Arg      E12       Serine protease   Pakistani        Severe                    Ahmed et al., 2004\
                                                                                                                 Ben-Yosef et al., 2001\
                                                                                                                 Lee et al., 2012

  c.1273T\>C             p.Cys425Arg      E12       Serine protease   Pakistani        N/A                       Lee et al., 2012

  c.1276G\>A             p.Ala426Thr      E12       Serine protease   Dutch            Mild                      Weegerink et al., 2011

  c.1291C\>T             p.Pro431Ser      E12       Serine protease   Italian          Severe                    Vozzi et al., 2014
  ------------------------------------------------------------------------------------------------------------------------------------------

N/A: not available.

[^1]: Academic Editor: J. Michael Wyss
